Rivastigmine is an inhibitor of acetylcholinesterase and carbamate-type butyrylcholinesterase, which promotes cholinergic neurotransmission, slowing down the degradation of acetylcholine, which is released by functionally intact cholinergic neurons. Thus, rivastigmine has a beneficial effect on cognitive deficits due to impaired cholinergic neurotransmission, with dementia associated with Alzheimer’s disease or Parkinson’s disease.
The medicine is used for symptomatic treatment from mild to moderate dementia due to Alzheimer’s disease, as well as moderate to moderate dementia in patients with idiopathic Parkinson’s disease.
Trade name: Rivastigmine ІС
Pharmaceutical form: capsules
Pharmacotherapeutic group: Psychoanaleptics. Drugs used for dementia. Cholinesterase inhibitors. Rivastigmine.
ATX Code N06D A03.
Registration number: №UA/16388/01/01, №UA/16388/01/02, №UA/16388/01/03, №UA/16388/01/04
Date of registration / valid until: 25.10.2017 / 25.10.2022
Packing: capsules №30 (10 × 3) in a blister, in a pack
Shelf life: 2 years
Legal сategory: prescription only medicine
Search